Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy

por Al-Shihabi, Ahmad, Chawla, Sant P., Hall, Frederick L., Gordon, Erlinda M.
Publicado 2018

Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report

por Kim, Seth, Federman, Noah, Gordon, Erlinda M., Hall, Frederick L., Chawla, Sant P.
Publicado 2017

Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists

por Gordon, Erlinda M., Ravicz, Joshua R., Liu, Seiya, Chawla, Sant P., Hall, Frederick L.
Publicado 2018

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer

por Chawla, Sant P., Bruckner, Howard, Morse, Michael A., Assudani, Nupur, Hall, Frederick L., Gordon, Erlinda M.
Publicado 2018

Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer

por Chawla, Sant P, Chua, Victoria S, Fernandez, Lita, Quon, Dorris, Blackwelder, William C, Gordon, Erlinda M, Hall, Frederick L
Publicado 2009

Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case repo...

por Morse, Michael A., Chawla, Sant P., Wong, Terence Z., Bruckner, Howard W., Hall, Frederick L., Gordon, Erlinda M.
Publicado 2021

Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma

por Chawla, Sant P, Chua, Victoria S, Fernandez, Lita, Quon, Doris, Saralou, Andreh, Blackwelder, William C, Hall, Frederick L, Gordon, Erlinda M
Publicado 2009